- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05957809
Structured Exercise Training in Newly Diagnosed Multiple Sclerosis
May 21, 2025 updated by: Feray Güngör, Istanbul University - Cerrahpasa
The Effects of Structured Exercise Training on Disease Course in Newly Diagnosed Multiple Sclerosis
the effectiveness of structured exercise training will be investigated for individuals with MS who are newly diagnosed and have no clinical problems.
Individuals with MS included in the study will be randomly divided into two groups a Structured Exercise Group (SEG) and a Control Group (CG).
In order to compare baseline and follow-up data, the Healthy Group (HG) will be taken and all three groups will be evaluated initially, 8. weeks and 24.
weeks with primary and secondary outcome measurements.
SEG, CG, and HG will be evaluated initially for postural sway, muscle strength, mobility, dexterity, cognitive function, trunk strength-endurance, and fatigue.
Afterward, SEG will receive structured exercise training consisting of clinically supervised aerobic exercise and resistance training on unstable surfaces for 8 weeks, 2 days a week, with a minimum session duration of 60 minutes.
Stretching and mobility exercises will be added to warm up and cool down before and after the program.
CG will be on the waiting list during this process.
At the end of 8 weeks, both groups will be reassessed with their initial assessment.
After the 8-week program, the SEG physical activity recommendation will be given and the KG group will continue on the waiting list, and a follow-up evaluation will be made in the 24th week.
This study will allow the comparison of newly diagnosed individuals with MS who do not have any physical or cognitive effects on neurological examination and healthy controls with objective and detailed evaluations, and will also reveal the evidence on the effects of planned structured exercises specific to individuals with newly diagnosed MS.
During the 24-week follow-up period, the change in the clinical status of individuals with MS who received or did not receive any exercise training can be interpreted.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
According to the data of the World Multiple Sclerosis (MS) atlas, the incidence of MS in our country is 51-100/100.000
and it is estimated that there are over 70.000 individuals with MS.
MS continues to be the most common cause of non-traumatic neurological disability in young adults with its increasing prevalence in our country as well as all over the world.
The most common problems seen in MS are deterioration of balance and postural control, decrease in muscle strength, gait problems, and cognitive and emotional functions.
These effects become more visible in the later stages of the disease, but a limited number of studies reveal that there is an insidious progression from the early period.
The topographical model of MS suggests that the burden of disease below the threshold is compensated by functional reserve, presents no physical problems, and symptoms become evident once the clinical threshold is crossed.
Furthermore, the evidence suggests that disease activity may be continued even during the relapse-remitting phase of the disease course, highlighting the need for the use of sensitive outcome measures that can detect early disorders.
Therefore, the involvement in individuals with newly diagnosed MS is ignored because it is not reflected in activities of daily living, is compensated by functional reserve because it is below the threshold value, and cannot be detected in the non-objective clinical neurological examination.
Rehabilitation approaches for individuals with newly diagnosed MS are needed in order to benefit from the protective effects of exercise and to prevent the effects from progressing.
Therefore, within the scope of our proposed project, the effectiveness of structured exercise training will be investigated for individuals with MS who are newly diagnosed and have no clinical problems.
Individuals with MS included in the study will be randomly divided into two groups a Structured Exercise Group (SEG) and a Control Group (CG).
In order to compare baseline and follow-up data, the Healthy Group (HG) will be taken and all three groups will be evaluated initially, 8. weeks and 24.
weeks with primary and secondary outcome measurements.
SEG, CG, and HG will be evaluated initially for postural sway, muscle strength, mobility, dexterity, cognitive function, trunk strength-endurance, and fatigue.
Afterward, SEG will receive structured exercise training consisting of clinically supervised aerobic exercise and resistance training on unstable surfaces for 8 weeks, 2 days a week, with a minimum session duration of 60 minutes.
Stretching and mobility exercises will be added to warm up and cool down before and after the program.
CG will be on the waiting list during this process.
At the end of 8 weeks, both groups will be reassessed with their initial assessment.
After the 8-week program, the SEG physical activity recommendation will be given and the KG group will continue on the waiting list, and a follow-up evaluation will be made in the 24th week.
This study will allow the comparison of newly diagnosed individuals with MS who do not have any physical or cognitive effects on neurological examination and healthy controls with objective and detailed evaluations, and will also reveal the evidence on the effects of planned structured exercises specific to individuals with newly diagnosed MS.
During the 24-week follow-up period, the change in the clinical status of individuals with MS who received or did not receive any exercise training can be interpreted.
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34147
- Feray Güngör
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Being diagnosed with MS according to McDonald diagnostic criteria
- EDSS below 2.5
- Diagnosis period less than 1 year
- Being between the ages of 18-45
- Volunteering to participate in the study
Exclusion Criteria:
- Apart from the MS diagnosis, orthopedic, neurological, psychological, etc., which will affect the evaluation results. have diseases
- Regular exercise and doing sports
- Being involved in another rehabilitation program
- Being pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1. Structured exercise group
This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.
|
This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes
|
|
No Intervention: 2. Control group
This group will be assessed at the beginning, 8. and 24.
weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Test of Sensory Integration of Balance Test
Time Frame: 24 weeks
|
Postural sway in "open eyes-firm surface, closed eyes-firm surface, open eyes-foam surface, closed eyes-foam surface" conditions will be evaluated with the Clinical Test of Sensory Integration of Balance.
|
24 weeks
|
|
Postural Stability Test
Time Frame: 24 weeks
|
Anterior-posterior, mediolateral and overall sway will be evaluated with the Postural Stability Test in Biodex Balance System.
|
24 weeks
|
|
Balance Error Scoring System Test
Time Frame: 24 weeks
|
Postural sway in tandem position and feet together position will be evaluated with Balance Error Scoring System in Biodex Balance System.
|
24 weeks
|
|
Muscle strength
Time Frame: 24 weeks
|
Quadriceps, hamstring, ankle dorsi and plantar flexors muscle strength will be assessed with Hand Held Dynamometer.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
2 Minute Walk Test
Time Frame: Baseline, 8th and 24th weeks
|
It will be used to evaluate walking speed.
|
Baseline, 8th and 24th weeks
|
|
Timed 25 Foot Walk Test
Time Frame: Baseline, 8th and 24th weeks
|
It will be used to evaluate walking distance.
|
Baseline, 8th and 24th weeks
|
|
Brief International Cognitive Assessment for MS (BICAMS)
Time Frame: Baseline, 8th and 24th weeks
|
BICAMS will be used to evaluate cognitive functions.
|
Baseline, 8th and 24th weeks
|
|
Curl-up
Time Frame: Baseline, 8th and 24th weeks
|
It will be used to evaluate trunk flexor muscle strength.
While the hips and knees are in 90º flexion position and the feet are fixed by the therapist, the individuals will be asked to flex their trunk and the number of repetitions done for 30 seconds will be recorded.
|
Baseline, 8th and 24th weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2023
Primary Completion (Actual)
March 20, 2025
Study Completion (Actual)
May 20, 2025
Study Registration Dates
First Submitted
June 20, 2023
First Submitted That Met QC Criteria
July 16, 2023
First Posted (Actual)
July 24, 2023
Study Record Updates
Last Update Posted (Actual)
May 25, 2025
Last Update Submitted That Met QC Criteria
May 21, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/68
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Structured exercise training
-
University Hospital, Basel, SwitzerlandTerminatedHeart Defects, CongenitalSwitzerland, Spain
-
Sheffield Teaching Hospitals NHS Foundation TrustCompleted
-
Gaia HospitalUniversidade do PortoCompleted
-
St. Joseph's Healthcare HamiltonNot yet recruitingGlaucoma | Dry Eye Disease (DED)
-
University Magna GraeciaCompletedPolycystic Ovary Syndrome | Infertility | AnovulationItaly
-
Guangdong Provincial People's HospitalPeople's Hospital of Xinjiang Uygur Autonomous Region; Yuebei People's Hospital and other collaboratorsRecruiting
-
Democritus University of ThraceUniversity of Crete (School of Medicine); University Hospital of Heraklion...CompletedChronic Non-specific Neck Pain | Chronic Non-specific Low-Back PainGreece
-
Universiti Sains MalaysiaActive, not recruitingLower Crossed SyndromeChina
-
Technical University of MunichCompletedHereditary Breast and Ovarian CancerGermany
-
Technical University of MunichUniversity of Cologne; University of Leipzig; University Hospital Schleswig-Holstein and other collaboratorsRecruitingHereditary Breast and Ovarian CancerGermany